Jeffrey Thibodeaux, MD
Urology · Lafayette, LANPI 1275634107
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,912 of the $7,869 with a category attached, or 87.8%. It is spread thinly across 39 manufacturers, the largest accounting for just 15.2% — the pattern of someone who eats at a lot of different presentations.
Across 338 payments — averaging $23.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$1K
- AbbVie$902
- Astellas Pharma US Inc$873
- Sumitomo Pharma America, Inc.$518
- Pfizer$465
- Coloplast$447
- plus $3K from 33 others
What the payments were for
- Travel & lodging$85911%
- Food & beverage$6,91288%
- Education$991%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 9 | $1,193 |
| AbbVie(2 entities) | 51 | $902 |
| Astellas Pharma US Inc | 56 | $873 |
| Sumitomo Pharma America, Inc. | 28 | $518 |
| Pfizer | 32 | $465 |
| Coloplast | 19 | $447 |
| Neotract Inc. | 5 | $399 |
| Johnson & Johnson | 12 | $319 |
| Dendreon Pharmaceuticals LLC | 16 | $295 |
| Endo Pharmaceuticals Inc. | 16 | $251 |
| Procept Biorobotics Corporation | 3 | $246 |
| Calyxo, Inc. | 1 | $179 |
| Accord Healthcare, Inc. | 10 | $173 |
| Merck | 8 | $148 |
| Urogen Pharma, Inc. | 6 | $136 |
| Boston Scientific | 5 | $131 |
| Blue Earth Diagnostics | 6 | $131 |
| Kerecis Limited | 1 | $100 |
| Antares Pharma, Inc. | 5 | $94 |
| Olympus America Inc. | 5 | $85 |
| Bayer | 5 | $83 |
| Myovant Sciences Inc. | 5 | $77 |
| Tolmar Pharmaceuticals, Inc. | 5 | $75 |
| Ferring Pharmaceuticals Inc. | 4 | $67 |
| Urovant Sciences Inc | 3 | $64 |
| Profound Medical Corp. | 1 | $54 |
| Novartis | 3 | $50 |
| Medtronic | 2 | $48 |
| Progenics Pharmaceuticals, Inc. | 2 | $47 |
| Hollister Incorporated | 2 | $40 |
| Endo USA, Inc. | 2 | $36 |
| AstraZeneca | 2 | $29 |
| Amgen | 2 | $27 |
| Zyla Life Sciences, Inc. | 1 | $25 |
| Axonics, Inc. | 1 | $18 |
| Telix Pharmaceuticals | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $13 |
| Photocure Inc | 1 | $11 |
| Civco Medical Instruments | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,226
- CVAC Aspiration System$179
- UroLift System$141
- AquaBeam Robotic System$135
- Tremfya$129
How this compares
$7,869 in reported general payments places this provider in the 75th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 159 | $95,528 |
| MyrbetriqMirabegron | 123 | $71,936 |
| Tamsulosin Hcl | 1,931 | $25,897 |
| Finasteride | 549 | $7,798 |
| NitrofurantoinNitrofurantoin Macrocrystal | 188 | $4,206 |
| Tolterodine Tartrate ErTolterodine Tartrate | 46 | $3,605 |
| Testosterone Cypionate | 88 | $2,987 |
| Potassium Citrate ErPotassium Citrate | 50 | $2,527 |
| Estradiol | 30 | $2,312 |
| Oxybutynin Chloride ErOxybutynin Chloride | 128 | $2,111 |
| CefuroximeCefuroxime Axetil | 179 | $2,082 |
| Bethanechol Chloride | 38 | $2,056 |
| Solifenacin Succinate | 64 | $1,729 |
| Silodosin | 20 | $1,462 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 117 | $1,417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $518 | $95,528159 claims |
| Astellas Pharma US IncMyrbetriq | $873 | $71,936123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 199 urology providers in Louisiana.
Other urology in Lafayette
- William RothLafayette$17K
- Thad BourqueLafayette$8K
- Christopher FontenotLafayette$6K
- Jeremy SpeegLafayette$6K
- Scott NeusetzerLafayette$6K
- Richard VanlangendonckNew Orleans$289K
- Gerard HenryBossier City$256K
- Ralph HendersonShreveport$211K
- Wayne HellstromNew Orleans$183K
- Colin GoudelockeNew Orleans$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.